ADVFN Logo ADVFN

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for monitor Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.
Pluri Inc

Pluri Inc (PLUR)

4.4281
0.1081
(2.50%)
Al cierre: 26 Febrero 3:00PM
4.4281
0.00
( 0.00% )
Fuera de horario: 4:35PM
Gráfico avanzado

Mejore su cartera: debates en tiempo real e ideas comerciales prácticas.

Estadísticas y detalles clave

Último Precio
4.4281
Postura de Compra
4.20
Postura de Venta
6.47
Volume Operado de la Acción
2,192
4.32 Rango del Día 4.54
4.07 Rango de 52 semanas 8.48
Capitalización de Mercado [m]
Precio Anterior
4.32
Precio de Apertura
4.37
Última hora de negociación
15:05:06
Volumen financiero
US$ 9,607
Precio Promedio Ponderado
4.3827
Volumen promedio (3 m)
10,936
Acciones en circulación
6,997,140
Rendimiento del Dividendo
-
Ratio Precio/Utilidad
-1.48
Beneficio por acción (BPA)
-2.99
turnover
326k
Beneficio neto
-20.89M

Acerca de Pluri Inc

Pluristem Therapeutics Inc is registered with the U.S. Security and Exchange Commission and incorporated in the state of Nevada. Pluristem Therapeutics Inc is primarely in the business of biological products (no diagnostic substances). For financial reporting, their fiscal year ends on June 30th. Th... Pluristem Therapeutics Inc is registered with the U.S. Security and Exchange Commission and incorporated in the state of Nevada. Pluristem Therapeutics Inc is primarely in the business of biological products (no diagnostic substances). For financial reporting, their fiscal year ends on June 30th. This page includes all SEC registration details as well as a list of all documents (S-1, Prospectus, Current Reports, 8-K, 10K, Annual Reports) filed by Pluristem Therapeutics Inc. Pluristem Therapeutics Inc is a US-based company which acts as a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The lead indications are critical limb ischemia, recovery after surgery for femoral neck fracture, and acute radiation syndrome. The company operations are focused on the research, development, clinical trials and manufacturing of cell therapeutics and related technologies. Mostrar más

Sector
Biological Pds,ex Diagnstics
Industria
Biological Pds,ex Diagnstics
Sitio web
Sede
Haifa, North, Isr
Fundado
-
Pluri Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker PLUR. The last closing price for Pluri was US$4.32. Over the last year, Pluri shares have traded in a share price range of US$ 4.07 to US$ 8.48.

Pluri currently has 6,997,140 shares in issue. The market capitalisation of Pluri is US$30.23 million. Pluri has a price to earnings ratio (PE ratio) of -1.48.

PLUR Últimas noticias

Período †Variación(Ptos)Variación %AperturaPrecio MáximoPrecio MínimoAvg. Vol. diarioPrecio Promedio Ponderado
1-0.2719-5.785106382984.74.74.2539314.3715767CS
40.02810.6386363636364.44.794.2355504.37879369CS
12-0.6919-13.5136718755.125.454.07109364.62596484CS
26-0.7019-13.68226120865.136.184.07178335.066074CS
52-1.3727-23.66397738245.80088.484.07283886.17986046CS
156-3.5719-44.64875811.57843.4488545996.37376969CS
260-3.5719-44.64875811.57843.4488545996.37376969CS

PLUR - Preguntas Frecuentes

¿Cuál es el precio actual de las acciones de Pluri?
El precio actual de las acciones de Pluri es US$ 4.4281
¿Cuántas acciones de Pluri están en circulación?
Pluri tiene 6,997,140 acciones en circulación
¿Cuál es la capitalización de mercado de Pluri?
La capitalización de mercado de Pluri es USD 30.23M
¿Cuál es el rango de negociación de 1 año para el precio de las acciones de Pluri?
Pluri ha negociado en un rango de US$ 4.07 a US$ 8.48 durante el último año
¿Cuál es el ratio PE (precio/beneficio) de Pluri?
El ratio precio/beneficio de Pluri es -1.48
¿Cuál es el ratio de efectivo a ventas de Pluri?
El ratio de efectivo a ventas de Pluri es 95.06
¿Cuál es la moneda de reporte de Pluri?
Pluri presenta sus resultados financieros en USD
¿Cuál es el último ingresos anual de Pluri?
El último ingresos anual de Pluri es USD 326k
¿Cuál es el último beneficio anual de Pluri?
El último beneficio anual de Pluri es USD -20.89M
¿Cuál es la dirección registrada de Pluri?
La dirección registrada de Pluri es MATAM ADVANCED TECHNOLOGY PARK, BUILDING NO. 5, HAIFA, NORTH, 3508409
¿Cuál es la dirección del sitio web de Pluri?
La dirección del sitio web de Pluri es www.pluristem.com
¿En qué sector industrial opera Pluri?
Pluri opera en el sector BIOLOGICAL PDS,EX DIAGNSTICS

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
ULYUrgent ly Inc
US$ 0.8668
(106.38%)
6.31M
CPOPPop Culture Group Company Ltd
US$ 1.36
(96.53%)
9.29M
BLMZBloomZ Inc
US$ 0.4997
(38.88%)
6.87M
NIXXNixxy Inc
US$ 2.10
(32.91%)
7.92M
ROOTRoot Inc
US$ 121.00
(22.58%)
118.53k
DMRCDigimarc Corporation
US$ 20.01
(-26.00%)
39.81k
SYTASiyata Mobile Inc
US$ 3.19
(-23.50%)
495.68k
TNDMTandem Diabetes Care Inc
US$ 27.20
(-19.02%)
310.54k
CLEUChina Liberal Education Holdings Ltd
US$ 0.0605
(-18.57%)
7.13M
SPGCSacks Parente Golf Inc
US$ 0.5997
(-18.08%)
1.52M
NVDANVIDIA Corporation
US$ 131.00
(-0.21%)
41.88M
CPOPPop Culture Group Company Ltd
US$ 1.36
(96.53%)
9.29M
NIXXNixxy Inc
US$ 2.10
(32.91%)
7.92M
CLEUChina Liberal Education Holdings Ltd
US$ 0.0605
(-18.57%)
7.13M
BLMZBloomZ Inc
US$ 0.4997
(38.88%)
6.87M

PLUR Finanzas

Finanzas

PLUR Discussion

Ver más
FDApproved FDApproved 12 horas hace
Bu¨hler makes new collaboration for cultivated meat

https://www.feedandadditive.com/buhler-makes-new-collaboration-for-cultivated-meat/
👍️ 1
FDApproved FDApproved 2 días hace
Today.....AACR IO 2025 | AACR | Meetings

Chief Scientific Officer Dr. Arthur Machlenkin will be giving a poster session titled “Advancing the allogeneic MAIT platform for targeting solid tumors” on Monday, February 24, 1:45-4pm
👍️ 1
FDApproved FDApproved 6 días hace
Strategic Collaboration for Scalable Cultivated Meat Production

Foodtech innovator Ever After Foods (EAF) and global food leader Bühler have announced a strategic collaboration to accelerate the commercial-scale production of cultivated meat. This partnership aims to provide food producers worldwide with efficient, cost-effective, and scalable cultivated meat production systems, addressing global food security and environmental challenges.

“The global food chain faces significant challenges if we are to successfully and sustainably feed our growing population. Powering cultivated meat production at scale with a patented production system, EAF will help the food industry keep pace with protein demands,” — Ian Roberts, CTO, Bühler

https://igrownews.com/ever-after-foods-latest-news/
👍️ 1
FDApproved FDApproved 6 días hace
Ever After Foods is now working closely with selected cultivated meat companies and food industry leaders to accelerate the development and deployment of its proprietary edible packed-bed (EPB™) technology platform.

https://vegconomist.com/manufacturing-technology/ever-after-foods-buhler-commercial-cultivated-meat-production-system/
👍️ 1
FDApproved FDApproved 1 semana hace
Israel’s Ever After Foods has partnered with Swiss manufacturing giant Bühler Group to produce cultivated meat at a mass scale with much smaller equipment.

https://www.greenqueen.com.hk/buhler-ever-after-foods-tnuva-cultivated-meat-bioreactors/
👍️ 1 ❤️ 1
Scott999 Scott999 2 semanas hace
Why doesn’t anyone ask why the company’s been around for a quarter century now and has yet to make any revenues. Where did the half billion dollars they’ve raised during that time go?
👍 1
FDApproved FDApproved 2 semanas hace
Q&A with Yaky Yanay, President and CEO, Pluri

https://www.citybiz.co/article/660081/qa-with-yaky-yanay-president-and-ceo-pluri/
👍️ 1
FDApproved FDApproved 2 semanas hace
February Company Presentation !!!

https://pluri-biotech.com/presentation/
👍️ 1
Scott999 Scott999 3 semanas hace
Like the 20 other markers they’ve entered, they’ll get the usual 0# market share. Unless they enter the clown nose market. Then they’d have a monopoly.

So George is good then?
👍️0
FDApproved FDApproved 3 semanas hace
Israel’s Pluri secures $6.5M strategic Investment, Enters Cacao market

According to reports. Global cacao market value was $13.5 billion in 2023, and is expected to grow by 8.2% to $23.5 billion by 2030

https://agrospectrumasia.com/2025/01/27/israels-pluri-secures-6-5m-strategic-investment-enters-cacao-market.html
👍️ 1
Scott999 Scott999 3 semanas hace
Ok there bud. How’s George doing? You know, your boss.
👍️0
FDApproved FDApproved 3 semanas hace
Thanks For Confirming That You Are Completely Clueless !!!
👍️ 1
Scott999 Scott999 3 semanas hace
What’s clueless eh? That they’re around 0 in shareholder equity? How much cash they got left? What’s it take to pay the 150 plus employees each quarter. That $10 million buys them what, 4 or 5 months? What’s gonna happen once they hit the pinks since they won’t regain compliance based on shareholder equity. Ya this is the year the cash cow for employees ends. The scams coming to an end soon.
👍️0
FDApproved FDApproved 3 semanas hace
Scotty.....We Enjoy Your Profound Cluelessness !!! Keep The Comedy Coming !!!
👍️ 1
Scott999 Scott999 3 semanas hace
That should get them to about 0 in shareholder equity. No compliance comprende. Belly up this year.
👍️0
FDApproved FDApproved 3 semanas hace
Pluri Secures Additional $3.5 Million Investment from Major Shareholder at Premium to Market, Bringing Total Recent Financings to $10 Million

https://pluri-biotech.com/releases/pluri-secures-additional-3-5-million-investment-from-major-shareholder-at-premium-to-market-bringing-total-recent-financings-to-10-million/
👍️ 1
FDApproved FDApproved 4 semanas hace
“The first cost estimates that we have applying Pluri’s technology into the production of Kokomodo cacao are very promising and will give Kokomodo a tremendous competitive advantage in this vertical.”

Asked about scaling plant cell culture, he added: “From day one, we have been growing cells in packed bed reactors that allow us to achieve real scale in relatively small bioreactors as our system is 20 times more efficient than a [typical] steel bioreactor [where cells grow in suspension].

“Our plan is to move aggressively and quickly to bring these solutions to market and our first step is to use bioreactors with five chambers of 200 liters capable of producing hundreds of kilos of cocoa and coffee. We anticipate that in 2026 this system will be available from Pluri for manufacturing across our subsidiaries. So when I’m talking about scaling up, it’s not a 10-year process, this is something that we see coming and coming soon.”

He added: “We are already discussing with players in the [coffee and chocolate] industry that are showing very significant interest in our solutions.”

Weinstein explained: “This is one of those rare opportunities you find in life as an investor, when you look at the quality of the people and the technology, it’s quite unique. The potential is explosive.

https://agfundernews.com/is-plant-cell-culture-a-scalable-way-to-futureproof-cocoa-and-coffee
👍️ 1
FDApproved FDApproved 4 semanas hace
New Company Presentation !!!

https://pluri-biotech.com/presentation/
👍️ 1
Scott999 Scott999 1 mes hace
Wow cocoa now. First the pretend steaks, then pretend coffee and now pretend cacao. Pretty good for a pretend company that’s going to the pinks in a few months.
👍️0
FDApproved FDApproved 1 mes hace
Kokomodo: This Israel-based company uses cell-cultured technology to navigate supply chain challenges by creating real, controlled, climate-resilient cocoa. This allows cocoa to be consistently produced year-round and anywhere in the world without relying on specific climates.

Pluri is acquiring a 71% stake in Kokomodo Ltd.

https://ir.mondelezinternational.com/news-releases/news-release-details/mondelez-international-selects-10-start-ups-participate-second
👍️ 1
FDApproved FDApproved 1 mes hace
Yaky Yanay, Chief Executive Officer and President of Pluri. “We are pleased that Mr. Weinstein understands our mission and will take part in shaping our strategy as we progress. We believe that Mr. Weinstein’s equity investment will strengthen our financial foundation and allow us to advance our entry into the cultivated cacao market, with the goal of positioning Pluri as a leader in this sector, where demand is growing and alternative agricultural solutions are needed to feed our global population. We believe that the synergy between Kokomodo’s advancements in cell line development and Pluri’s industrial-scale production creates a strong foundation for innovation, positioning the company to lead the field of cultivated cacao and set new benchmarks in cultivated cacao technologies.”
👍️ 1
FDApproved FDApproved 1 mes hace
IMO....Pluri Will Control The Cultured Chocolate Market ! $$$/b]
👍️ 1
FDApproved FDApproved 1 mes hace
Private placement of $6.5 million with a global investor and entrepreneur, Mr. Alejandro Weinstein, who will join Pluri’s Board of Directors
Pluri to purchase approximately 71% of Kokomodo Ltd.’s shares, a leading AgTech company focused on the production of cacao, subject to shareholder approval.

https://pluri-biotech.com/releases/pluri-secures-6-5-million-strategic-investment-at-premium-to-market-enters-cacao-market-through-acquisition/
👍️ 1
FDApproved FDApproved 1 mes hace
Pluri CEO & President Yaky Yanay

👍️0
FDApproved FDApproved 1 mes hace
Pluri CEO & President Yaky Yanay

👍️ 1
FDApproved FDApproved 1 mes hace
Nasdaq has determined to grant the Company an extension of time to regain compliance with the Stockholders’ Equity Requirement until May 24, 2025.
👍️ 1
midastouch017 midastouch017 1 mes hace
Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

As previously reported, on November 25, 2024, Pluri Inc., or Pluri or the Company, received a deficiency letter, or the Nasdaq Letter, from the Listing Qualifications Department of The Nasdaq Stock Market LLC, or Nasdaq, notifying the Company that it is not in compliance with Nasdaq Listing Rule 5550(b)(1), which requires the Company to maintain a minimum of $2,500,000 in stockholders’ equity for continued listing on The Nasdaq Capital Market, or the Stockholders’ Equity Requirement, nor is it in compliance with either of the alternative listing standards, market value of listed securities of at least $35 million or net income of $500,000 from continuing operations in the most recently completed fiscal year, or in two of the three most recently completed fiscal years.

On January 6, 2025, the Company submitted a plan to regain compliance, or the Compliance Plan. Based on the Compliance Plan, Nasdaq has determined to grant the Company an extension of time to regain compliance with the Stockholders’ Equity Requirement until May 24, 2025. If the Company fails to evidence compliance by the required deadline, the Company may be subject to delisting. At that time, the Company may appeal Staff’s determination to a Hearings Panel.

The Company intends to take all reasonable measures available to regain compliance under the Nasdaq Listing Rules and remain listed on Nasdaq. However, there can be no assurance the Company will ultimately regain compliance with all applicable requirements for continued listing.

Neither the Nasdaq Letter nor the Company’s noncompliance have an immediate effect on the listing or trading of the Company’s common shares, which will continue to trade on The Nasdaq Capital Market under the symbol “PLUR”.

A non event, eh FDA?
👍️0
FDApproved FDApproved 1 mes hace
MORE MAIT CELL INDICATIONS !!!

In some embodiments, there is provided a method for treating a subject suffering from an autoimmune disease or disorder, comprising administering to said subject a composition comprising the population of engineered IVB CAR-MAIT cells disclosed herein. In some embodiments, the engineered IVB CAR-MAIT cells are allogeneic to said subject. In some embodiments, the autoimmune disease or disorder comprises systemic lupus erythematosus (SLE), refractory SLE, pemphigus vulgaris, multiple sclerosis, type I diabetes, rheumatoid arthritis, celiac disease, pernicious anemia, inflammatory myopathies, myasthenia gravis, or adrenalitis, or a combination thereof.
In other embodiments, there is provided a method of treating a subject infected with a pathogen, comprising administering to the subject a composition comprising a population of placental IVB CAR-MAIT cells, wherein the IVB MAIT cells are allogeneic to said subject.

In certain embodiments, these IVB MAIT cells do not comprise an exogenous antigen receptor. In some embodiments, the pathogen is a bacterial pathogen, a viral pathogen, or a fungal pathogen. In certain embodiments, a bacterial pathogen comprises an antibiotic resistant bacteria or bacterial treatment resistant bacteria. In some embodiments, a bacterial pathogen comprises a

Mycobacterium tuberculosis bacteria. In some embodiments, a fungal pathogen comprises an invasive Aspergillus. In some embodiments, a viral pathogen comprises a cytomegalovirus, a hepatitis B virus, or a hepatitis C virus. In some embodiments, the infectious condition treated by a method disclosed herein, is limited to site specific infections, for example wherein an infection is limited to a specific site or organ. In some embodiments, an infection treated by a method disclosed herein comprises a post-surgical infection.
👍️ 1
FDApproved FDApproved 1 mes hace
MAIT CELL PATENT !!!

In some aspects of the invention, the cell composition disclosed herein is for use in therapy. In some optional embodiments, the cell composition may be used for treating a subject having a tumor or malignancy. Exemplifying use of the cell composition of the invention is for a subject afflicted with a tumor such as, but not limited to: blood cancer, melanoma, breast cancer, colon cancer, kidney cancer, liver cancer, lung cancer, ovary cancer, pancreatic cancer, prostate cancer, uterine cancer, cervical cancer, bladder cancer, stomach cancer, head and neck cancer, brain cancer, skin cancer and sarcoma.

In some aspects of the invention a method of treating a subject having a tumor or malignancy is provided, wherein the method comprises administering to the subject a cell composition according to any optional embodiment as defined above. The tumor treated may be for example, blood cancer, melanoma, breast cancer, colon cancer, kidney cancer, liver cancer, lung cancer, ovary cancer, pancreatic cancer, prostate cancer, uterine cancer, cervical cancer, bladder cancer, stomach cancer, head and neck cancer, brain cancer, skin cancer and sarcoma. Preferably, but not necessarily, the cell composition for treating the subject is adapted for cell therapy and the population comprises at least 109 viable cells, of which at least 90% are TCRVa7.2+ CD161hlgh.

In some embodiments, the engineered placental MAIT cells used for treating the subject are allogeneic to said subject. In other options, the engineered placental MAIT cells are partly histocompatible with the subject, or the engineered placental MAIT cells are not histocompatible with the subject.

In some aspects of the invention, a method of treating a subject infected with a pathogen is provided. The pathogen may be either one of a bacterial pathogen, viral pathogen, or a fungal pathogen, and the method comprises administering to the subject a cell composition according to any suitable optional embodiment as defined above.

In some additional aspects of the invention, method of treating a subject suffering from a fibrotic disease or condition, method of treating a subject suffering from a senescence-associated disease or condition, method of treating a subject having an allogeneic transplantation, method of treating a subject suffering from an autoimmune disease or disorder, are provided, wherein all methods above comprising administering to the subject in need a cell composition according to any suitable optional embodiment as defined above.

Yet, in accordance with additional aspects of the invention, a method of treating a subject infected with a pathogen is provided, the method comprising administering to the subject a composition comprising a population of MAIT cells derived from placenta. The population of MAIT cells according to this embodiment is not engineered MAIT cells, and the cells do not express exogenous CAR. The pathogen may be for example, a bacterial pathogen, a viral pathogen, or a fungal pathogen. In some specific examples the bacterial pathogen may comprise a Mycobacterium tuberculosis bacteria. In some embodiments, the bacterial pathogen comprises an antibiotic resistant bacteria or bacterial treatment resistant bacteria. In some other specific examples, the fungal pathogen may comprise an invasive Aspergillus. In some further examples, the viral pathogen may comprise a cytomegalovirus, a hepatitis B virus, or a hepatitis C optionally the infection is as a result of a post-surgical infection. Preferably, but not necessarily, the MAIT cells used for treating the subject according to this aspect of the invention are allogeneic to said subject.
👍️ 1
FDApproved FDApproved 1 mes hace
2 Very Important Pluri MAIT Cell Patents Posted Today !!!

https://patentscope.wipo.int/search/en/result.jsf?_vid=P11-M5ZHNP-55415
👍️ 1
FDApproved FDApproved 1 mes hace
Yaky Yanay: Revolutionizing Biotech with Pluri's Cell-Based Solutions

👍️ 1
FDApproved FDApproved 1 mes hace
Cellular Agriculture Redefines The Future Of Coffee

https://stir-tea-coffee.com/tea-coffee-news/cellular-agriculture-redefines-the-future-of-coffee/
👍️ 1
Scott999 Scott999 2 meses hace
They pretend cured Covid, IC, ICS, Beurgers, Solid Tumours, Preeclampsia, ARS, Hip and others I’m sure over forgotten over the decades. So why not pretend cure cancer too.

Pretend all the way to the pinks with -$10,000,000.00 in shareholder equity.
👍️0
FDApproved FDApproved 2 meses hace
Can a Placenta Cure Cancer?

BIU’s collaboration with biotechnology company Pluri suggests it can

https://www.biu.ac.il/en/article/582414#:~:text=At%20the%20heart%20of%20this%20research%20lies%20a,MAIT%20cells%20from%20placentas%20donated%20by%20healthy%20women.
👍️ 1
Scott999 Scott999 2 meses hace
Should only see about another 4 or 5 of these before they finally shut this company runs out of money. Took 25 years but 2025 will mark the end of this legal scam. Those 150 employees plus will milk every last penny they can, and most likely steal whatever they can from the office. They were taught well by the head clowns.

-$10,000,000.00 in shareholder equity.
Trading at fresh ALL TIME lows
Nuf said
👍️0
FDApproved FDApproved 2 meses hace
January Company Presentation !!!

https://pluri-biotech.com/presentation/
👍️ 1
Scott999 Scott999 2 meses hace
New all time lows to go along with the nearly -10,000,000.00 in shareholder equity. Keep an eye out on the Israeli Kijiji. They’re going to be selling office furniture real soon.
👍️0
Scott999 Scott999 2 meses hace
How they gonna overcome almost -$10,000,000.00 in shareholder equity. The one that’s gonna get them on the pinks. But the $500,000,000.00 that they’ve blown with nothing to show for it becomes irrelevant when you look at the big picture. Like the good ole Zzatt used to say, “WE GOT ZZIENTISTS” wonder how his 200,000 shares are doing.
👍️0
FDApproved FDApproved 2 meses hace
“For us, it’s not just a theoretical exercise, we can produce hundreds of kilos in our labs. This is not something that we intend to develop in five years’ time; we know how to scale this process.” Yaky Yanay, CEO, Pluri

https://agfundernews.com/eggs-coffee-chocolate-and-the-culture-wars-foodtech-in-2024
👍️ 1
Monksdream Monksdream 2 meses hace
PLUR under $5

👍️0
Scott999 Scott999 2 meses hace
Not when you’re around - $9 million in shareholder equity. That’s what happens when you blow through half a billion dollars with literally zero to show for it. Even the pr says ARS will s all they got on the go and we all know they failed on that one already.

Clowns are just about done with their schemes to dupe investors out of their money.
👍️0
FDApproved FDApproved 2 meses hace
This Bodes Well For The Space !!!

The FDA granted approval of Ryoncil to Mesoblast, Inc.

https://www.fda.gov/news-events/press-announcements/fda-approves-first-mesenchymal-stromal-cell-therapy-treat-steroid-refractory-acute-graft-versus-host
👍️ 1
Scott999 Scott999 3 meses hace
-$5,283,000 shareholder equity as of Sept 30th. They lost over $6,000,000 last quarter so by now with a bit more than half a month to go in this quarter, they should be hitting -$10,000,000 in shareholder equity.

Next stop…the pinks.
👍️0
FDApproved FDApproved 3 meses hace
U.S. National Institutes of Health to Fund $4.2 Million Contract to Advance Development of Pluri’s PLX-R18 in Conjunction with U.S. DoD as a Medical Countermeasure for Hematopoietic Acute Radiation Syndrome

https://pluri-biotech.com/releases/u-s-national-institutes-of-health-to-fund-4-2-million-contract-to-advance-development-of-pluris-plx-r18-in-conjunction-with-u-s-dod-as-a-medical-countermeasure-for-hematopoietic-acute-radi/
👍️ 2
midastouch017 midastouch017 3 meses hace
4.8315 -0.1685 (-3.37%)
As of 9:45:46 AM EST. Market Open.
Volume 30,082
Avg. Volume 25,828
Wow, the market sure is impressed!
👍️0
FDApproved FDApproved 3 meses hace
Huge Pluri Biotech Patent Posted Today !!!

Coffee/Cacao And Every Other Plant On The Planet !!!

https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2024252382&_cid=P12-M4LD2S-44544-1
👍️ 2
midastouch017 midastouch017 3 meses hace
Pluristem Receives Response from U.S. BARDA for Acute Radiation Syndrome Research Proposal
https://pluri-biotech.com/releases/pluristem-receives-response-from-u-s-barda-for-acute-radiation-syndrome-research-proposal/

At this time, BARDA has chosen not to move forward with the funding of the current proposal. The decision is based on BARDA’s technical considerations as determined by a Technical Evaluation Panel.
Other factors considered by BARDA included BARDA’s current strategic needs, availability of funds and resources, and an aim to balance BARDA’s current portfolio. In its response, BARDA encouraged and invited Pluristem to participate in future relevant BARDA opportunities.

“While we had hoped to receive the funding of the proposal, we understand that at this time there are a set of parameters that led BARDA to this decision.
We will continue to advance our current ARS projects with the U.S. National Institute of Allergy and Infectious Diseases (NIAID), U.S. Department of Defense (DOD), Fukushima Hospital and the University in Japan and pursue additional opportunities and collaborations in this area.
👍️0
midastouch017 midastouch017 3 meses hace
BARDA rejects Pluristem's request for radiation study funding
By Nick Paul Taylor Mar 3, 2020 8:40am
https://www.fiercebiotech.com/biotech/barda-rejects-pluristem-s-request-for-radiation-study-funding
👍️0
Scott999 Scott999 3 meses hace
They had to evaluate? Lmao. They started this ARS crap a decade ago. They need to “evaluate”. That’s absolutely hilarious.

Wheres the beef? Thought they were on the cusp of growing steaks and milk and coffee beans. Can’t forget about all those things too. Boy you’d think with all the presentations on their partnership with another Israeli company would have something to announce by now no?

Maybe the whopping $300k they made last quarter will suffice. Since they’re nominated for CDMO shortlist and actually announce this massive news release, I’m sure everyone’s clamouring to use these clowns.

They’ve been legally scamming people for 25 years now. An accomplishment I’m not sure can be touched. To milk half a BILLION off of shareholders and after 25 years have revenues of $300,000 for a quarter, these guys should be locked up truly.

Karma to all involved in this fraud. Big fat karma.
👍️0
FDApproved FDApproved 3 meses hace
Observe !!!

https://pluri-biotech.com/releases/pluri-evaluates-readiness-for-mass-production-of-plx-r18-for-acute-radiation-syndrome-amid-rising-nuclear-threat-concerns/
👍️ 2